The Billion-Dollar Question: Which Emerging Agents Have Blockbuster PotentialDecision ResourcesDecember 18, 2006 19 Pages - SKU: DECR1399790 |
| Countries covered: Global Introduction In 2005, more than half of the $405 billion worldwide pharmaceutical market was generated from sales of more than 100 blockbuster products. From the beginning of 2006 through mid 2008, however, 19 of these agents (20% of blockbuster sales) will face patent expiry. The potential generic threat from these expiries poses a challenge for both the companies that manufacture them and the industry at large. Questions Answered in This Spectrum Report Almost 20% of the market value for pharmaceuticals in 2005 (from about 16 products) faces generic competition by mid 2008. What are the top blockbuster drugs facing challenges from patent expiries? What agents are manufacturers developing in an effort to fi ll this void? We forecast that eight new blockbuster products will launch between the end of 2006 and mid 2008. What approaches will these new drugs take in addressing their respective indications? How successful will these emerging agents be in these indications? The new crop of blockbusters slated to debut in the next few years will bring new players to the list of blockbuster-producing companies. Which companies will become new members of the blockbuster club? How will their approaches in creating and sustaining these drugs differ from those taken by other companies that have created blockbusters? Scope
|
Additional Information
Companies Mentioned in This Spectrum Report
- Abbott Laboratories
- Amgen
- Amylin
- AstraZeneca
- AtheroGenics
- Banyu
- Centocor
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Janssen
- Johnson & Johnson
- Merck
- Neurochem
- Neurocrine Biosciences
- Novartis
- Pfi zer
- Sanofi -Aventis
- Schering-Plough
- Takeda
- Tanabe
- UCB
- Wyeth
More Global Prescription Drugs Reports
Global Pharmaceuticals & Medicine Manufacturing by
IBISWorld
Global Pharmaceuticals & Medicine Manufacturing This industry comprises companies that manufacture biological, medicinal and pharmaceutical products in various forms including ampoules, tablets, capsules, vials, ointments, powders, ...
Ophthalmic Drugs: World Market Prospects 2012-2022 by
Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry
What are the commercial prospects for treating eye disorders? Visiongain's report shows you ...
Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry by
iCD Research
Synopsis
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...
Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry by
iCD Research
Synopsis
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by
Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...
See all reports like this >>
Related Markets
Prescription Drugs Reports
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Chinese Markets for Hepatitis Drugs
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
